

ERRATUM Open Access



Erratum to: Arum Palaestinum with isovanillin, linolenic acid and β-sitosterol inhibits prostate cancer spheroids and reduces the growth rate of prostate tumors in mice

Caitlin Cole¹, Thomas Burgoyne², Annie Lee^{1,3}, Lisa Stehno-Bittel^{1,4} and Gene Zaid^{2*}

Erratum

Unfortunately, the original version of this article [1] contained an error. The presentation of Fig five was incorrect due to the figure not appearing along with the information and the legend. This is an update and Erratum to the original article. The corrected Figure five can be seen below (Fig. 1):

Author details

¹Likarda, LLC, 2002 W. 39th Ave, Kansas City 66103, KS, USA. ²Genzada Pharmaceuticals, LLC, 205 S. Broadway, Sterling 67579, KS, USA. ³Rockhurst University, 1100 Rockhurst Rd, Kansas City 64110, MO, USA. ⁴University of Kansas Medical Center, MS 2002, 3901 Rainbow Blvd., Kansas City 66160, KS, USA.

Received: 8 September 2015 Accepted: 8 September 2015 Published online: 14 September 2015

Reference

 Cole C, Burgoyne T, Lee A, Stehno-Bittel L, Zaid G. Arum Palaestinum with isovanillin, linolenic acid and β-sitosterol inhibits prostate cancer spheroids and reduces the growth rate of prostate tumors in mice. BMC Complement Altern Med. 2015;15:264.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit



²Genzada Pharmaceuticals, LLC, 205 S. Broadway, Sterling 67579, KS, USA



^{*} Correspondence: Gene.zaid@genzada.com




Fig. 1 Tumor volume. Tumor volume was measured in 3 dimensions with calipers. The size of the tumors and the rate of tumor growth were both statistically greater in the vehicle-treated mice, compared to the GZ17. **indicates p < 0.001; *indicates p < 0.001 for comparisons between effects of days of treatment and baseline tumor volume within groups (repeated ANOVA)